Targeted cancer therapies work by singling out gene mutations that drive tumor growth, then using a drug to block the effects of the mutant gene. But tumors consist of millions of cells that may collectively harbor hundreds of different “driver” mutations. That means therapies for some cancers will have to target more than one mutation at a time to be successful. To help solve the problem, researchers at Oregon Health & Science University devised … Read More
Posts Tagged ‘leukemia’
Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A disease with a three- to five-year life expectancy became, for most patients, a chronic, long-term condition managed with a daily pill. And this week, researchers published the outcomes of people treated for more than 10 years with the drug imatinib (Gleevec), ushered from lab to clinical … Read More
New findings open a path for developing desperately needed therapies for the most frequently diagnosed leukemia in adults. Leukemia paves the way for its deadly advance by manipulating the micro-environment within the bone marrow, triggering changes that suppress healthy, blood-forming stem cells while favoring the growth of cancer. The loss of hematopoietic stem cells results in bleeding, shortness of breath, fatigue, and infections. Researchers led by OHSU’s Peter Kurre, M.D., now have uncovered one of the … Read More
Gleevec binds to the kinase domain of the mutant enzyme BCR-ABL1 Life expectancy in patients with chronic myeloid leukemia has soared to a level almost equal to that of the general population, according to a Swedish study quantifying the life-saving impact of Gleevec, the targeted therapy ushered from lab bench to clinical success by Brian Druker, M.D., director of the OHSU Knight Cancer Institute.
Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments. Less than 25 percent of newly diagnosed patients survive beyond five years with a standard of care based on 40-year-old chemotherapy agents. The research initiative, Beat AML, is supplying a stock of drug candidates and treatment ideas, a dozen of which were presented on Dec. 5-8 at … Read More
A preclinical study led by an OHSU Knight Cancer Institute physician may point the way to more effective tests for recurrence of acute myeloid leukemia. Nearly half of patients diagnosed with AML will eventually experience a relapse, even with the best available treatment. And those patients must undergo bone marrow biopsies to detect relapses, says Peter Kurre, M.D., who specializes in pediatric hematology/oncology and blood disorders. Bone marrow biopsies are uncomfortable for the patient … Read More